Valuation: TAKE Solutions Limited

Capitalization 5.86B 60.84M 52.27M 47.83M 45.42M 83.64M 85.06M 572M 222M 2.77B 228M 224M 9.67B P/E ratio 2024
-2.54x
P/E ratio 2025 2.61x
Enterprise value 5.83B 60.49M 51.97M 47.55M 45.16M 83.16M 84.57M 569M 221M 2.76B 227M 222M 9.61B EV / Sales 2024
5.18x
EV / Sales 2025 -
Free-Float
40.47%
Yield 2024 *
-
Yield 2025 -
1 day+4.98%
1 week-14.44%
Current month-40.20%
1 month-49.08%
3 months-45.99%
6 months-13.49%
Current year-36.08%
1 week 23.15
Extreme 23.15
28.35
1 month 23.15
Extreme 23.15
50.14
Current year 23.15
Extreme 23.15
50.14
1 year 8.33
Extreme 8.33
50.14
3 years 6.51
Extreme 6.51
50.14
5 years 6.51
Extreme 6.51
74.6
10 years 6.51
Extreme 6.51
308.25
Manager TitleAgeSince
Compliance Officer - 2026-01-27
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Director/Board Member - 2025-05-23
Director/Board Member 43 2025-05-23
Director/Board Member 47 2025-05-23
Change 5d. change 1-year change 3-years change Capi.($)
+4.98%-14.44%+161.31%+46.30% 37.35M
+3.61%+1.44%-15.53%-16.09% 41.61B
-0.06%-5.68%+28.33%+28.14% 32.58B
-0.89%+0.15%+265.12%+468.83% 30.69B
+2.18%-0.43%+21.00%-11.58% 28.84B
-2.97%-4.23%+23.72%+16.24% 25.65B
-1.19%-0.43% - - 14.76B
-2.76%+1.68%+168.71%+4,393.86% 13.74B
-2.30%-3.79%+116.09%+97.98% 11.98B
+2.13%+3.65%+9.81%+1.46% 12.3B
Average +0.27%-3.64%+86.51%+558.35% 21.22B
Weighted average by Cap. +0.24%-2.07%+68.19%+386.40%

Financials

2024 2025
Net sales 656M 6.81M 5.85M 5.35M 5.08M 9.36M 9.52M 64.08M 24.84M 310M 25.56M 25.02M 1.08B -
Net income -1.2B -12.42M -10.67M -9.76M -9.27M -17.07M -17.36M -117M -45.28M -566M -46.6M -45.61M -1.97B 375M 3.89M 3.34M 3.06M 2.9M 5.35M 5.44M 36.59M 14.18M 177M 14.6M 14.29M 618M
Net Debt 362M 3.76M 3.23M 2.96M 2.81M 5.17M 5.26M 35.39M 13.72M 171M 14.12M 13.82M 598M -33.71M -350K -301K -275K -261K -481K -489K -3.29M -1.28M -15.95M -1.31M -1.29M -55.59M
Logo TAKE Solutions Limited
Take Solutions Limited is an India-based contract research organization (CRO), which is engaged in supporting pharma, biotech and devices companies. The Company offers clients a combination of full-service clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance/safety services. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry network forums. Its digital healthcare services include medical decision-making (artificial intelligence and machine learning), and cloud adoption & mobility. Its global roster of clients includes large and small biopharmaceutical and device companies, United States federal agencies like Centers for Disease Control and Prevention (CDC) and the United States Department of Defense (DoD), as well as generics manufacturers. The Company's subsidiary is Ecron Acunova Limited.
Employees
2
Date Price Change Volume
26-05-19 25.53 +4.98% 481,685
26-05-18 24.32 -5.00% 267,962
26-05-15 25.60 -4.97% 43,213
26-05-14 26.94 -4.97% 34,309
26-05-13 28.35 -4.99% 173,298